» Articles » PMID: 21147906

Fertility-sparing Surgery in Early-stage Cervical Cancer: Indications and Applications

Overview
Specialty Oncology
Date 2010 Dec 15
PMID 21147906
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

This article describes the surgical and pathologic findings of fertility-sparing radical trachelectomy using a standardized surgical technique, and reports the rate of posttrachelectomy outcomes. The authors analyzed a prospectively maintained database of all patients with FIGO stage IA1-IB1 cervical cancer admitted to the operating room for planned fertility-sparing radical abdominal trachelectomy. Sentinel node mapping was performed through cervical injection. Between November 2001 and May 2010, 98 consecutive patients with FIGO stage IA1-IB1 cervical cancer and a median age of 32 years (range, 6-45 years) underwent a fertility-sparing radical trachelectomy. The most common histology was adenocarcinoma in 54 patients (55%) and squamous carcinoma in 42 (43%). Lymph-vascular invasion was seen in 38 patients (39%). FIGO stages included IA1 (with lymph-vascular invasion) in 10 patients (10%), IA2 in 9 (9%), and IB1 in 79 (81%). Only 15 (15%) needed immediate completion radical hysterectomy because of intraoperative findings. Median number of nodes evaluated was 22 (range, 3-54), and 16 (16%) patients had positive pelvic nodes on final pathology. Final trachelectomy pathology showed no residual disease in 44 (45%) cases, dysplasia in 5 (5%), and adenocarcinoma in situ in 3 (3%). Overall, 27 (27%) patients needed hysterectomy or adjuvant pelvic radiation postoperatively. One (1%) documented recurrence was fatal at the time of this report. Cervical adenocarcinoma and lymph-vascular invasion are common features of patients selected for radical trachelectomy. Most patients can undergo the operation successfully with many having no residual invasive disease; however, nearly 27% of all selected cases will require hysterectomy or postoperative chemoradiation for oncologic reasons. Investigation into alternative fertility-sparing adjuvant therapy in patients with node-positive disease is needed.

Citing Articles

The top 100 most cited articles on fertility-sparing treatments for cervical cancer: A bibliometric analysis.

Jiang X, Feng C, Sun W, Zhang T, Cui B Heliyon. 2024; 10(11):e31738.

PMID: 38828299 PMC: 11140800. DOI: 10.1016/j.heliyon.2024.e31738.


Fertility-sparing options for cancer patients.

Alur-Gupta S, Fruchtman H, Paroder V Abdom Radiol (NY). 2023; 48(5):1618-1628.

PMID: 36884058 DOI: 10.1007/s00261-023-03839-8.


Variation in outcome reporting in studies of fertility-sparing surgery for cervical cancer: A systematic review.

Yong N, Cooper N, Yorke S, Baran C, Khan K, Tan A BJOG. 2022; 130(2):163-175.

PMID: 36367451 PMC: 10108142. DOI: 10.1111/1471-0528.17342.


[Uterine Cervical Cancer: Emphasis on Revised FIGO Staging 2018 and MRI].

Jang W, Song J Taehan Yongsang Uihakhoe Chi. 2022; 82(5):1083-1102.

PMID: 36238389 PMC: 9432380. DOI: 10.3348/jksr.2021.0113.


Fertility-Sparing Surgery in Gynecologic Cancer: A Systematic Review.

Schuurman T, Zilver S, Samuels S, Schats W, Amant F, van Trommel N Cancers (Basel). 2021; 13(5).

PMID: 33670929 PMC: 7975326. DOI: 10.3390/cancers13051008.